의약품 약물전달 시장 : 투여 경로별, 용도별 - 세계 기회 분석 및 산업 예측(2023-2032년)

Pharmaceutical Drug Delivery Market By Route of Administration, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 8,064,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,512,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

의약품 약물전달 시장은 2022년 1조 4,987억 2,000만 달러로 2023년부터 2032년까지 4.4%의 CAGR로 2032년에는 2조 3,072억 7,000만 달러에 달할 것으로 추정됩니다.

심혈관 질환, 당뇨병, 암, 호흡기 질환과 같은 만성 질환은 장기적인 약물 치료가 특징입니다. 이러한 질환은 증상을 억제하고, 질병의 진행을 늦추고, 삶의 질을 유지하기 위해 정기적인 약물 투여가 필요합니다. 이에 따라 효과적인 약물전달 시스템에 대한 수요가 증가하고 있으며, 이는 시장 성장의 원동력이 되고 있습니다. 국제당뇨병연맹(IDF)에 따르면, 2021년에는 성인 당뇨병 환자 약 4명 중 3명이 중저소득 국가에 살고 있으며, 서태평양 지역에서는 약 2억 6천만 명이 당뇨병 진단을 받은 것으로 추정됩니다.

예를 들어, 2022년 5월 미국 식품의약국(FDA)은 제2형 당뇨병을 치료하기 위한 새로운 주사 전달 제품인 Mounjaro를 승인했습니다. 이처럼 당뇨병 유병률의 증가는 당뇨병 치료에 매우 효과적인 고급 인슐린 전달 시스템의 개발로 이어졌습니다. 또한 심혈관 질환, 관절염, 신경 퇴행성 질환, 골다공증과 같은 노화 관련 질환의 유병률 증가는 효과적인 약물전달에 대한 큰 수요를 창출하고 있습니다.

예를 들어, 2023년 1월, 제약업계의 세계 리더인 바이오젠은 알츠하이머병 치료제 LEQEMBI를 미국 식품의약국(FDA)의 승인을 받았으며, LEQEMBI는 알츠하이머병을 효과적으로 치료하는 단일 클론 항체 지향성 정맥 내 약물전달 약물입니다. 이처럼 새로운 표적 약물전달 및 방출 제어 제제의 개발은 시장 성장에 더욱 기여할 것입니다. 그러나 엄격한 규제 요건은 새로운 약물전달 기술의 시간, 비용 및 복잡성을 증가시켜 시장 성장을 저해할 수 있습니다. 또한 새로운 약물전달의 연구 개발과 관련된 높은 비용은 시장 성장에 부정적인 영향을 미칩니다.

한편, 첨단 약물전달 시스템에 대한 수요 증가는 예측 기간 동안 시장 성장에 유리한 기회를 창출할 것으로 예상됩니다. 이는 만성 질환의 유병률 증가, 치료 결과의 개선, 첨단 약물전달 시스템 개발에 유리한 상환 정책의 가용성에 기인합니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
  • 공급 기업의 교섭력
  • 구매자의 교섭력
  • 대체품의 위협
  • 신규 참여업체의 위협
  • 경쟁의 강도
• 시장 역학
  • 성장 촉진요인
    • 다양한 만성질환 증가
    • 약물전달 시스템 기술 진보
  • 성장 억제요인
    • 약물전달 승인에 관한 엄격한 규제 요건
  • 기회
    • 첨단 전달 시스템에 대한 수요 증가
• COVID-19의 시장에 대한 영향 분석

제4장 의약품 약물전달 시장 : 투여 경로별

• 개요
• 경구 약물전달
• 경비 약물전달
• 경안 약물전달
• 국소 약물전달
• 기타 약물전달

제5장 의약품 약물전달 시장 : 용도별

• 개요
• 암
• 당뇨병
• 심혈관질환
• 기타

제6장 의약품 약물전달 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카, 중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타 지역

제7장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10개사 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제8장 기업 개요

• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Bayer AG
• Cipla Ltd
• Amgen Inc.

ksm

영문 목차

영문목차

According to a new report published by Allied Market Research, titled, "Pharmaceutical Drug Delivery Market," The pharmaceutical drug delivery market was valued at $1,498.72 billion in 2022, and is estimated to reach $2307.27 billion by 2032, growing at a CAGR of 4.4% from 2023 to 2032.

Chronic diseases, such as cardiovascular disorders, diabetes, cancer, and respiratory diseases, are characterized by long-term medication treatment. These conditions require regular administration of drugs to control symptoms, slow disease progression, or maintain quality of life. This has increased the demand for effective drug delivery systems, thereby driving the market growth. According to International Diabetes Federation (IDF), in 2021, it was estimated that about 3 in 4 adults with diabetes live in low and middle-income countries and approximately 206 million people were diagnosed with diabetes in western pacific.

For instance, in May 2022, U.S. Food and Drug Administration (FDA), approved new injectable delivery product, Mounjaro to treat type 2 diabetes. Thus, the rise in prevalence of diabetes has led to the development of advanced insulin delivery systems, which are highly effective to treat diabetes. In addition, growth in prevalence of age-related diseases such as cardiovascular disorders, arthritis, neurodegenerative diseases, and osteoporosis have created a significant demand for effective drug delivery.

For instance, in January 2023, Biogen Inc., one of the global leader in pharmaceutical industry, received U.S. Food and Drug Administration (FDA) approval for LEQEMBI to treat Alzheimer's disease. LEQEMBI is a monoclonal antibody directed intravenous drug delivery medication that effectively treats Alzheimer's disease. Thus, development of new targeted drug delivery and controlled release formulation further contribute toward the market growth. However, stringent regulatory requirements can increase the time, cost, and complexity of new drug delivery technologies and restrain market growth. Furthermore, high costs associated with research and development of new drug delivery negatively impact market growth.

On the other hand, an increase in demand for advanced drug delivery systems is expected to create lucrative opportunities for market growth during the forecast period. This is attributed to the increase in prevalence of chronic diseases, enhanced treatment outcomes, and availability of favorable reimbursement policies for the development of advanced drug delivery systems.

The pharmaceutical drug delivery market is segmented on the basis of route of administration, application, and region. On the basis of route of administration, the market is classified into oral drug delivery, nasal drug delivery, ocular drug delivery, topical drug delivery, and other drug delivery. As per application, the market is categorized into cancer, diabetes, cardiovascular diseases, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global pharmaceutical drug delivery market are: Bayer AG, Cipla Ltd, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Amgen Inc., Pfizer Inc., Sanofi. Key players operating in the market have adopted product launch and product approval as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical drug delivery market analysis from 2022 to 2032 to identify the prevailing pharmaceutical drug delivery market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the pharmaceutical drug delivery market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global pharmaceutical drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Route of Administration

• Topical drug delivery
• Other drug delivery
• Oral drug delivery
• Nasal drug delivery
• Ocular drug delivery

By Application

• Cancer
• Diabetes
• Cardiovascular Diseases
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Amgen Inc.
• Bayer AG
• Cipla Ltd
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Bargaining power of suppliers
  • 3.3.2. Bargaining power of buyers
  • 3.3.3. Threat of substitutes
  • 3.3.4. Threat of new entrants
  • 3.3.5. Intensity of rivalry
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in prevalence of various chronic diseases
    • 3.4.1.2. Technological advancement in drug delivery systems

• 3.4.2. Restraints
  • 3.4.2.1. Stringent regulatory requirements for the approval of pharmaceutical drug delivery

• 3.4.3. Opportunities
  • 3.4.3.1. Increase in demand for advanced delivery systems

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Oral drug delivery
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Nasal drug delivery
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Ocular drug delivery
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Topical drug delivery
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Other drug delivery
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country

CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Cancer
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Diabetes
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Cardiovascular Diseases
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Others
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION

• 6.1. Overview
  • 6.1.1. Market size and forecast By Region
• 6.2. North America
  • 6.2.1. Key trends and opportunities
  • 6.2.2. Market size and forecast, by Route of Administration
  • 6.2.3. Market size and forecast, by Application
  • 6.2.4. Market size and forecast, by country
    • 6.2.4.1. U.S.
    • 6.2.4.1.1. Key market trends, growth factors and opportunities
    • 6.2.4.1.2. Market size and forecast, by Route of Administration
    • 6.2.4.1.3. Market size and forecast, by Application
    • 6.2.4.2. Canada
    • 6.2.4.2.1. Key market trends, growth factors and opportunities
    • 6.2.4.2.2. Market size and forecast, by Route of Administration
    • 6.2.4.2.3. Market size and forecast, by Application
    • 6.2.4.3. Mexico
    • 6.2.4.3.1. Key market trends, growth factors and opportunities
    • 6.2.4.3.2. Market size and forecast, by Route of Administration
    • 6.2.4.3.3. Market size and forecast, by Application
• 6.3. Europe
  • 6.3.1. Key trends and opportunities
  • 6.3.2. Market size and forecast, by Route of Administration
  • 6.3.3. Market size and forecast, by Application
  • 6.3.4. Market size and forecast, by country
    • 6.3.4.1. Germany
    • 6.3.4.1.1. Key market trends, growth factors and opportunities
    • 6.3.4.1.2. Market size and forecast, by Route of Administration
    • 6.3.4.1.3. Market size and forecast, by Application
    • 6.3.4.2. France
    • 6.3.4.2.1. Key market trends, growth factors and opportunities
    • 6.3.4.2.2. Market size and forecast, by Route of Administration
    • 6.3.4.2.3. Market size and forecast, by Application
    • 6.3.4.3. UK
    • 6.3.4.3.1. Key market trends, growth factors and opportunities
    • 6.3.4.3.2. Market size and forecast, by Route of Administration
    • 6.3.4.3.3. Market size and forecast, by Application
    • 6.3.4.4. Italy
    • 6.3.4.4.1. Key market trends, growth factors and opportunities
    • 6.3.4.4.2. Market size and forecast, by Route of Administration
    • 6.3.4.4.3. Market size and forecast, by Application
    • 6.3.4.5. Spain
    • 6.3.4.5.1. Key market trends, growth factors and opportunities
    • 6.3.4.5.2. Market size and forecast, by Route of Administration
    • 6.3.4.5.3. Market size and forecast, by Application
    • 6.3.4.6. Rest of Europe
    • 6.3.4.6.1. Key market trends, growth factors and opportunities
    • 6.3.4.6.2. Market size and forecast, by Route of Administration
    • 6.3.4.6.3. Market size and forecast, by Application
• 6.4. Asia-Pacific
  • 6.4.1. Key trends and opportunities
  • 6.4.2. Market size and forecast, by Route of Administration
  • 6.4.3. Market size and forecast, by Application
  • 6.4.4. Market size and forecast, by country
    • 6.4.4.1. Japan
    • 6.4.4.1.1. Key market trends, growth factors and opportunities
    • 6.4.4.1.2. Market size and forecast, by Route of Administration
    • 6.4.4.1.3. Market size and forecast, by Application
    • 6.4.4.2. China
    • 6.4.4.2.1. Key market trends, growth factors and opportunities
    • 6.4.4.2.2. Market size and forecast, by Route of Administration
    • 6.4.4.2.3. Market size and forecast, by Application
    • 6.4.4.3. India
    • 6.4.4.3.1. Key market trends, growth factors and opportunities
    • 6.4.4.3.2. Market size and forecast, by Route of Administration
    • 6.4.4.3.3. Market size and forecast, by Application
    • 6.4.4.4. Australia
    • 6.4.4.4.1. Key market trends, growth factors and opportunities
    • 6.4.4.4.2. Market size and forecast, by Route of Administration
    • 6.4.4.4.3. Market size and forecast, by Application
    • 6.4.4.5. South Korea
    • 6.4.4.5.1. Key market trends, growth factors and opportunities
    • 6.4.4.5.2. Market size and forecast, by Route of Administration
    • 6.4.4.5.3. Market size and forecast, by Application
    • 6.4.4.6. Rest of Asia-Pacific
    • 6.4.4.6.1. Key market trends, growth factors and opportunities
    • 6.4.4.6.2. Market size and forecast, by Route of Administration
    • 6.4.4.6.3. Market size and forecast, by Application
• 6.5. LAMEA
  • 6.5.1. Key trends and opportunities
  • 6.5.2. Market size and forecast, by Route of Administration
  • 6.5.3. Market size and forecast, by Application
  • 6.5.4. Market size and forecast, by country
    • 6.5.4.1. Brazil
    • 6.5.4.1.1. Key market trends, growth factors and opportunities
    • 6.5.4.1.2. Market size and forecast, by Route of Administration
    • 6.5.4.1.3. Market size and forecast, by Application
    • 6.5.4.2. Saudi Arabia
    • 6.5.4.2.1. Key market trends, growth factors and opportunities
    • 6.5.4.2.2. Market size and forecast, by Route of Administration
    • 6.5.4.2.3. Market size and forecast, by Application
    • 6.5.4.3. South Africa
    • 6.5.4.3.1. Key market trends, growth factors and opportunities
    • 6.5.4.3.2. Market size and forecast, by Route of Administration
    • 6.5.4.3.3. Market size and forecast, by Application
    • 6.5.4.4. Rest of LAMEA
    • 6.5.4.4.1. Key market trends, growth factors and opportunities
    • 6.5.4.4.2. Market size and forecast, by Route of Administration
    • 6.5.4.4.3. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

• 7.1. Introduction
• 7.2. Top winning strategies
• 7.3. Product Mapping of Top 10 Player
• 7.4. Competitive Dashboard
• 7.5. Competitive Heatmap
• 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

• 8.1. F. Hoffmann-La Roche Ltd.
  • 8.1.1. Company overview
  • 8.1.2. Key Executives
  • 8.1.3. Company snapshot
  • 8.1.4. Operating business segments
  • 8.1.5. Product portfolio
  • 8.1.6. Business performance
• 8.2. GlaxoSmithKline plc
  • 8.2.1. Company overview
  • 8.2.2. Key Executives
  • 8.2.3. Company snapshot
  • 8.2.4. Operating business segments
  • 8.2.5. Product portfolio
  • 8.2.6. Business performance
• 8.3. Johnson & Johnson
  • 8.3.1. Company overview
  • 8.3.2. Key Executives
  • 8.3.3. Company snapshot
  • 8.3.4. Operating business segments
  • 8.3.5. Product portfolio
  • 8.3.6. Business performance
• 8.4. Merck & Co., Inc.
  • 8.4.1. Company overview
  • 8.4.2. Key Executives
  • 8.4.3. Company snapshot
  • 8.4.4. Operating business segments
  • 8.4.5. Product portfolio
  • 8.4.6. Business performance
• 8.5. Novartis AG
  • 8.5.1. Company overview
  • 8.5.2. Key Executives
  • 8.5.3. Company snapshot
  • 8.5.4. Operating business segments
  • 8.5.5. Product portfolio
  • 8.5.6. Business performance
  • 8.5.7. Key strategic moves and developments
• 8.6. Pfizer Inc.
  • 8.6.1. Company overview
  • 8.6.2. Key Executives
  • 8.6.3. Company snapshot
  • 8.6.4. Operating business segments
  • 8.6.5. Product portfolio
  • 8.6.6. Business performance
• 8.7. Sanofi S.A.
  • 8.7.1. Company overview
  • 8.7.2. Key Executives
  • 8.7.3. Company snapshot
  • 8.7.4. Operating business segments
  • 8.7.5. Product portfolio
  • 8.7.6. Business performance
• 8.8. Bayer AG
  • 8.8.1. Company overview
  • 8.8.2. Key Executives
  • 8.8.3. Company snapshot
  • 8.8.4. Operating business segments
  • 8.8.5. Product portfolio
  • 8.8.6. Business performance
• 8.9. Cipla Ltd
  • 8.9.1. Company overview
  • 8.9.2. Key Executives
  • 8.9.3. Company snapshot
  • 8.9.4. Operating business segments
  • 8.9.5. Product portfolio
  • 8.9.6. Business performance
• 8.10. Amgen Inc.
  • 8.10.1. Company overview
  • 8.10.2. Key Executives
  • 8.10.3. Company snapshot
  • 8.10.4. Operating business segments
  • 8.10.5. Product portfolio
  • 8.10.6. Business performance

관련자료